Clinical Trials Browser

Phase 1/2 × Terminated × Metastatic Castrate-Resistant Prostate Cancer × Clear all

NCT02607228 2020-12-08

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Phase 1/2 Terminated

31 enrolled 22 charts

Metastatic Castrate-Resistant Prostate Cancer